Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
12 stopped studies mapped to Breast Inflammatory Carcinoma and descendants · 100% state a reason
Over the 12 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03101748 | Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination… | Phase 1 / Phase 2 | terminated | Apr 5, 2017 | M.D. Anderson Cancer Center | \<75% accrued | Enrollment / accrual |
| NCT05041101 | Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer | Phase 1 / Phase 2 | terminated | Sep 10, 2021 | M.D. Anderson Cancer Center | Termination was requested by study supporter IKENA oncology | Other (stated, no rule matched) |
| NCT01938833 | Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer | Phase 1 / Phase 2 | terminated | Sep 10, 2013 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Closed by Sponsor | Other (stated, no rule matched) |
| NCT05177796 | Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the… | Phase 2 | withdrawn | Jan 5, 2022 | M.D. Anderson Cancer Center | 0 participants recruited | Enrollment / accrual |
| NCT03872388 | Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who… | Phase 2 | terminated | Mar 13, 2019 | M.D. Anderson Cancer Center | Due to slow accrual | Enrollment / accrual |
| NCT06057636 | Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study | N/A | withdrawn | Sep 28, 2023 | The University of Tennessee, Knoxville | Unable to recruit participants | Enrollment / accrual |
| NCT02658812 | Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be… | Phase 2 | terminated | Jan 20, 2016 | M.D. Anderson Cancer Center | Per PI | Other (stated, no rule matched) |
| NCT05093387 | SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative… | Phase 1 | withdrawn | Oct 26, 2021 | Northwestern University | funding issues and pharmacy preparation for the drug | Funding |
| NCT03184558 | Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC | Phase 2 | terminated | Jun 12, 2017 | BerGenBio ASA | Based on planned futility assessment | Efficacy / futility |
| NCT01755130 | Laser Optoacoustic and Ultrasonic Imaging System Assembly in Finding Changes in Tumors in… | N/A | terminated | Dec 24, 2012 | M.D. Anderson Cancer Center | due to lack of funding | Funding |
| NCT02892734 | Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative… | Phase 2 | terminated | Sep 8, 2016 | Northwestern University | Slow accrual | Enrollment / accrual |
| NCT00016276 | Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and… | Phase 3 | terminated | Sep 4, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Feb 12, 2026source: clinicaltrials